the Dissection of Lymph Node Posterior to Right Recurrent Laryngeal Nerve for Papillary Thyroid Carcinoma

Launched by ZHEJIANG UNIVERSITY · Jan 22, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new way to treat patients with papillary thyroid carcinoma (PTC) who may have lymph node metastases, which means cancer spreading to nearby lymph nodes. The trial has two parts. In the first part, researchers looked at 2,000 participants who underwent standard surgery to remove the thyroid and nearby lymph nodes. They collected information about the patients' age, tumor size, and other factors to create a prediction model that helps determine the likelihood of cancer spreading to specific lymph nodes behind a nerve in the neck.

In the second part of the trial, another group of 2,000 participants, who were predicted to not have cancer spread to those lymph nodes, were randomly divided into two groups. One group had the lymph nodes removed as a routine part of surgery, while the other group did not. The goal is to see if avoiding surgery on those lymph nodes can lead to similar recovery outcomes. To be eligible for the trial, participants need to be between 18 and 80 years old, have primary treatment for PTC, and agree to join the study after understanding what it involves. If you or a loved one fit these criteria, you may have the opportunity to contribute to important research that could improve future treatment options for thyroid cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Phase I:
• • 1. aged from 18 years old to 80 years old;
• • 2. the primary treatment of patients with right or bilateral PTC;
• • 3. patients will voluntarily enter the study after informed consent.
• Phase II:
• • 1. aged from 18 years old to 80 years old;
• • 2. the primary treatment of patients with right or bilateral PTC predicted to have no LN-prRLN metastasis by the "prediction model of LN-prRLN";
• • 3. patients will voluntarily enter the study after informed consent.
• Exclusion Criteria:
• • 1. patients refused to participate in the study;
• • 2. non first operation patients;
• • 3. other malignant tumor history;
• • 4. distant metastasis;
• • 5. history of neck trauma.